OBJECTIVE: To compare human T-cell lymphotrophic virus type I (HTLV-I) seropositive and seronegative women for symptoms and signs of spasticity. BACKGROUND: Infection with HTLV-I causes tropical spastic paraparesis/ HTLV-I-associated myelopathy (TSP/HAM). Certain populations, including female commercial sex workers (FSW), are at increased risk of developing this infection. Fewer than 5% of HTLV-I-seropositive persons develop TSP/HAM, which is typically associated with spasticity. METHODS: Cross-sectional study of 255 registered FSW in Callao, Perú, involving a questionnaire detailing demographics and neurologic symptoms, standard neurologic examination, quantitative assessment of spasticity (QSA) of muscle tone, and serologic testing for HTLV-I. Participants and examiners were blinded to serology results. RESULTS: On the questionnaire and neurologic examination, none of the 32 HTLV-I-seropositive or 223 seronegative women had signs or symptoms of spasticity. However, mean values on QSA were significantly higher among seropositive women (27.1 Newton-meters/radian [N-m/r]) than among seronegative women (21.6 N-m/r, p = 0.01), indicating a subclinical increase in lower extremity tone. With values of QSA divided into tertiles, and the first tertile serving as the comparison group, the odds ratio for seropositivity was 1.4 (95% confidence interval [CI] 1.0 to 2.0) in the second and 3.1 (95% CI 2.2 to 4.3) in the third tertile, after adjusting for age and place of birth. CONCLUSIONS: Although a standard neurologic evaluation could not distinguish between women with and without HTLV-I infection, QSA indicated significantly increased lower extremity tone in those with infection. Long-term follow-up will determine whether these subclinical findings in asymptomatic women progress to overt TSP/HAM.
OBJECTIVE: To compare human T-cell lymphotrophic virus type I (HTLV-I) seropositive and seronegative women for symptoms and signs of spasticity. BACKGROUND:Infection with HTLV-I causes tropical spastic paraparesis/ HTLV-I-associated myelopathy (TSP/HAM). Certain populations, including female commercial sex workers (FSW), are at increased risk of developing this infection. Fewer than 5% of HTLV-I-seropositive persons develop TSP/HAM, which is typically associated with spasticity. METHODS: Cross-sectional study of 255 registered FSW in Callao, Perú, involving a questionnaire detailing demographics and neurologic symptoms, standard neurologic examination, quantitative assessment of spasticity (QSA) of muscle tone, and serologic testing for HTLV-I. Participants and examiners were blinded to serology results. RESULTS: On the questionnaire and neurologic examination, none of the 32 HTLV-I-seropositive or 223 seronegative women had signs or symptoms of spasticity. However, mean values on QSA were significantly higher among seropositive women (27.1 Newton-meters/radian [N-m/r]) than among seronegative women (21.6 N-m/r, p = 0.01), indicating a subclinical increase in lower extremity tone. With values of QSA divided into tertiles, and the first tertile serving as the comparison group, the odds ratio for seropositivity was 1.4 (95% confidence interval [CI] 1.0 to 2.0) in the second and 3.1 (95% CI 2.2 to 4.3) in the third tertile, after adjusting for age and place of birth. CONCLUSIONS: Although a standard neurologic evaluation could not distinguish between women with and without HTLV-I infection, QSA indicated significantly increased lower extremity tone in those with infection. Long-term follow-up will determine whether these subclinical findings in asymptomatic women progress to overt TSP/HAM.
Authors: E L Murphy; J Fridey; J W Smith; J Engstrom; R A Sacher; K Miller; J Gibble; J Stevens; R Thomson; D Hansma; J Kaplan; R Khabbaz; G Nemo Journal: Neurology Date: 1997-02 Impact factor: 9.910
Authors: S Z Wiktor; P Piot; J M Mann; N Nzilambi; H Francis; G Vercauteren; W A Blattner; T C Quinn Journal: J Infect Dis Date: 1990-06 Impact factor: 5.226
Authors: R F Khabbaz; W W Darrow; T M Hartley; J Witte; J B Cohen; J French; P S Gill; J Potterat; R K Sikes; R Reich Journal: JAMA Date: 1990-01-05 Impact factor: 56.272
Authors: F S Wignall; K C Hyams; I A Phillips; J Escamilla; A Tejada; O Li; F Lopez; G Chauca; S Sanchez; C R Roberts Journal: J Med Virol Date: 1992-09 Impact factor: 2.327
Authors: K Nakashima; S Kashiwagi; W Kajiyama; M Hirata; J Hayashi; A Noguchi; K Urabe; K Minami; Y Maeda Journal: Am J Epidemiol Date: 1995-02-15 Impact factor: 4.897
Authors: E Gotuzzo; J Sánchez; J Escamilla; C Carrillo; I A Phillips; L Moreyra; W Stamm; R Ashley; E L Roggen; J Kreiss Journal: J Infect Dis Date: 1994-04 Impact factor: 5.226
Authors: Davi Tanajura Costa; André Luiz Muniz Alves dos Santos; Néviton Matos de Castro; Isadora Cristina de Siqueira; Edgar Marcelino de Carvalho Filho; Marshall Jay Glesby Journal: Arq Neuropsiquiatr Date: 2012-04 Impact factor: 1.420
Authors: J R Zunt; S M Montano; I Beck; J Ov Alarcón; L M Frenkel; C T Bautista; R Price; W T Longstreth Journal: J Neurovirol Date: 2006-12 Impact factor: 2.643
Authors: Daniel J Morgan; Marina F Caskey; Cristiane Abbehusen; Jamary Oliveira-Filho; Cesar Araujo; Aurelia F Porto; Silvane Braga Santos; Gloria O Orge; Maria Jose Joia; Andre L Muniz; Isadora Siqueira; Marshall J Glesby; Edgar Carvalho Journal: AIDS Res Hum Retroviruses Date: 2007-12 Impact factor: 2.205
Authors: José-Manuel Ramos-Rincón; Sonia Ortiz-Martínez; María-Esteyner Vásquez-Chasnamote; Eva de-Miguel-Balsa; Olga-Nohelia Gamboa-Paredes; Michael-John Talledo-Albujar; Giovanni López-Campana; Juan Carlos Celis-Salinas; Laura Prieto-Pérez; Miguel Górgolas-Hernández; Martin Casapía-Morales Journal: Pathogens Date: 2021-02-25
Authors: Beatriz Helena B Vasconcelos; Givago S Souza; Tatiana G C P Barroso; Luiz Carlos L Silveira; Rita Catarina M Sousa; Bianca Callegari; Marília B Xavier Journal: PLoS One Date: 2016-03-21 Impact factor: 3.240